Literature DB >> 2469491

Expression of protooncogene c-myb in normal human hematopoietic cells.

M B Kastan1, D J Slamon, C I Civin.   

Abstract

Expression of the protooncogene, c-myb, in various subpopulations of normal human hematopoietic cells was characterized. Cells expressing the immature cell surface marker, CD34 (My10), were isolated by immune adherence with the "panning" technique or immunomagnetic microspheres and were shown to be strongly positive for c-myb protein expression in an immunoperoxidase assay. The CD34+ progenitor cell population was further separated into myeloid plus erythroid progenitors (CD34+, CD10-) v B-lymphoid precursors (coexpressing CD34 and CD10) by two-color FACS. Both CD34+ progenitor cell subsets strongly expressed c-myb protein by the immunoperoxidase assay. A flow cytometric assay was then developed which permitted simultaneous detection of a cell-surface antigen (to characterize lineage and stage of maturation) and the nuclear oncoprotein. This assay confirmed that CD34+ cells were strongly positive for c-myb expression and also allowed quantitative comparisons of c-myb expression in selected populations of other normal hematopoietic cells. Most human bone marrow cells appear to express some level of c-myb protein, although the CD34+ progenitor cell population expresses the highest amount.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2469491

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Transgene insertion in proximity to the c-myb gene disrupts erythroid-megakaryocytic lineage bifurcation.

Authors:  Harumi Y Mukai; Hozumi Motohashi; Osamu Ohneda; Norio Suzuki; Masumi Nagano; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

2.  Stage-related proliferative activity determines c-myb functional requirements during normal human hematopoiesis.

Authors:  D Caracciolo; D Venturelli; M Valtieri; C Peschle; A M Gewirtz; B Calabretta
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

3.  The highly conserved DNA-binding domains of A-, B- and c-Myb differ with respect to DNA-binding, phosphorylation and redox properties.

Authors:  S Bergholtz; T O Andersen ; K B Andersson; J Borrebaek; B Lüscher; O S Gabrielsen
Journal:  Nucleic Acids Res       Date:  2001-09-01       Impact factor: 16.971

4.  Cytochemically unreactive neutrophils from subjects with myeloperoxidase (MPO) deficiency show a complex pattern of immunoreactivity with anti-MPO monoclonal antibodies: a flow cytometric and immunocytochemical study.

Authors:  F Lanza; A Latorraca; P Musto; L Ferrari; S Moretti; G Zabucchi; M Carotenuto; G L Castoldi
Journal:  Ann Hematol       Date:  1991-08       Impact factor: 3.673

5.  c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.

Authors:  Shenghao Jin; Huiwu Zhao; Yan Yi; Yuji Nakata; Anna Kalota; Alan M Gewirtz
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

6.  Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb.

Authors:  Nikla Emambokus; Alexandros Vegiopoulos; Ben Harman; Eric Jenkinson; Graham Anderson; Jon Frampton
Journal:  EMBO J       Date:  2003-09-01       Impact factor: 11.598

7.  Conformation Dynamics of the Intrinsically Disordered Protein c-Myb with the ff99IDPs Force Field.

Authors:  Xiang Guo; Jincheng Han; Ray Luo; Hai-Feng Chen
Journal:  RSC Adv       Date:  2017-06-07       Impact factor: 3.361

Review 8.  Interstitial Deletions Generating Fusion Genes.

Authors:  Ioannis Panagopoulos; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2021 May-Jun       Impact factor: 4.069

9.  Expression of p89(c-Mybex9b), an alternatively spliced form of c-Myb, is required for proliferation and survival of p210BCR/ABL-expressing cells.

Authors:  G Manzotti; S A Mariani; F Corradini; R Bussolari; V Cesi; J Vergalli; G Ferrari-Amorotti; V Fragliasso; A R Soliera; S Cattelani; G Raschellà; T L Holyoake; B Calabretta
Journal:  Blood Cancer J       Date:  2012-05-11       Impact factor: 11.037

Review 10.  MYB oncoproteins: emerging players and potential therapeutic targets in human cancer.

Authors:  Ylenia Cicirò; Arturo Sala
Journal:  Oncogenesis       Date:  2021-02-26       Impact factor: 7.485

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.